Phosphodiesterases: Emerging therapeutic targets for neonatal pulmonary hypertension

Kathryn N. Farrow, Robin H Steinhorn

Research output: Chapter in Book/Report/Conference proceedingChapter

21 Citations (Scopus)

Abstract

Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. Because of the heterogeneous group of disorders, the therapeutic approach and response often depends on the underlying disease. In many of these conditions, there is evidence that cyclic nucleotide signaling and specifically phosphodiesterases (PDEs) are disrupted. PDE inhibitors represent an emerging class of pulmonary vasodilators in adults. Studies are now under way to evaluate the utility, efficacy, and safety of such therapies in infants with pulmonary hypertension.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
Pages251-277
Number of pages27
Volume204
DOIs
StatePublished - 2011
Externally publishedYes

Publication series

NameHandbook of Experimental Pharmacology
Volume204
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Phosphoric Diester Hydrolases
Pulmonary Hypertension
Meconium Aspiration Syndrome
Bronchopulmonary Dysplasia
Phosphodiesterase Inhibitors
Cyclic Nucleotides
Vasodilator Agents
Heart Diseases
Sepsis
Newborn Infant
Safety
Lung
Therapeutics
Congenital Diaphragmatic Hernias

Keywords

  • Bronchopulmonary dysplasia
  • cAMP
  • cGMP
  • Congenital diaphragmatic hernia
  • Nitric oxide
  • Persistent pulmonary hypertension of the newborn
  • Phosphodiesterase
  • Prostacyclin

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

Farrow, K. N., & Steinhorn, R. H. (2011). Phosphodiesterases: Emerging therapeutic targets for neonatal pulmonary hypertension. In Handbook of Experimental Pharmacology (Vol. 204, pp. 251-277). (Handbook of Experimental Pharmacology; Vol. 204). https://doi.org/10.1007/978-3-642-17969-3_11

Phosphodiesterases : Emerging therapeutic targets for neonatal pulmonary hypertension. / Farrow, Kathryn N.; Steinhorn, Robin H.

Handbook of Experimental Pharmacology. Vol. 204 2011. p. 251-277 (Handbook of Experimental Pharmacology; Vol. 204).

Research output: Chapter in Book/Report/Conference proceedingChapter

Farrow, KN & Steinhorn, RH 2011, Phosphodiesterases: Emerging therapeutic targets for neonatal pulmonary hypertension. in Handbook of Experimental Pharmacology. vol. 204, Handbook of Experimental Pharmacology, vol. 204, pp. 251-277. https://doi.org/10.1007/978-3-642-17969-3_11
Farrow KN, Steinhorn RH. Phosphodiesterases: Emerging therapeutic targets for neonatal pulmonary hypertension. In Handbook of Experimental Pharmacology. Vol. 204. 2011. p. 251-277. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/978-3-642-17969-3_11
Farrow, Kathryn N. ; Steinhorn, Robin H. / Phosphodiesterases : Emerging therapeutic targets for neonatal pulmonary hypertension. Handbook of Experimental Pharmacology. Vol. 204 2011. pp. 251-277 (Handbook of Experimental Pharmacology).
@inbook{06efae3c793c43c0bbc9d632df0061e9,
title = "Phosphodiesterases: Emerging therapeutic targets for neonatal pulmonary hypertension",
abstract = "Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. Because of the heterogeneous group of disorders, the therapeutic approach and response often depends on the underlying disease. In many of these conditions, there is evidence that cyclic nucleotide signaling and specifically phosphodiesterases (PDEs) are disrupted. PDE inhibitors represent an emerging class of pulmonary vasodilators in adults. Studies are now under way to evaluate the utility, efficacy, and safety of such therapies in infants with pulmonary hypertension.",
keywords = "Bronchopulmonary dysplasia, cAMP, cGMP, Congenital diaphragmatic hernia, Nitric oxide, Persistent pulmonary hypertension of the newborn, Phosphodiesterase, Prostacyclin",
author = "Farrow, {Kathryn N.} and Steinhorn, {Robin H}",
year = "2011",
doi = "10.1007/978-3-642-17969-3_11",
language = "English (US)",
isbn = "9783642179686",
volume = "204",
series = "Handbook of Experimental Pharmacology",
pages = "251--277",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Phosphodiesterases

T2 - Emerging therapeutic targets for neonatal pulmonary hypertension

AU - Farrow, Kathryn N.

AU - Steinhorn, Robin H

PY - 2011

Y1 - 2011

N2 - Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. Because of the heterogeneous group of disorders, the therapeutic approach and response often depends on the underlying disease. In many of these conditions, there is evidence that cyclic nucleotide signaling and specifically phosphodiesterases (PDEs) are disrupted. PDE inhibitors represent an emerging class of pulmonary vasodilators in adults. Studies are now under way to evaluate the utility, efficacy, and safety of such therapies in infants with pulmonary hypertension.

AB - Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. Because of the heterogeneous group of disorders, the therapeutic approach and response often depends on the underlying disease. In many of these conditions, there is evidence that cyclic nucleotide signaling and specifically phosphodiesterases (PDEs) are disrupted. PDE inhibitors represent an emerging class of pulmonary vasodilators in adults. Studies are now under way to evaluate the utility, efficacy, and safety of such therapies in infants with pulmonary hypertension.

KW - Bronchopulmonary dysplasia

KW - cAMP

KW - cGMP

KW - Congenital diaphragmatic hernia

KW - Nitric oxide

KW - Persistent pulmonary hypertension of the newborn

KW - Phosphodiesterase

KW - Prostacyclin

UR - http://www.scopus.com/inward/record.url?scp=79960906108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960906108&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-17969-3_11

DO - 10.1007/978-3-642-17969-3_11

M3 - Chapter

C2 - 21695644

AN - SCOPUS:79960906108

SN - 9783642179686

VL - 204

T3 - Handbook of Experimental Pharmacology

SP - 251

EP - 277

BT - Handbook of Experimental Pharmacology

ER -